Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Mass Balance and PK Study of 14C-labelled GFT505 in Healthy Volunteers
NCT02142127Phase 1Completed
- Sponsor
- Genfit
- Start
- Apr 2014
- Primary completion
- Jun 2014
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 1, open-label, single-arm trial of elafibranor in Nonalcoholic steatohepatitis (NASH) and primary biliary cholangitis (PBC), sponsored by Genfit. Primary endpoint: Excretion balance of radiocarbon. Started Apr 2014; status: completed.
02
Drugs
elafibranor
03
Conditions
Nonalcoholic steatohepatitis (NASH)primary biliary cholangitis (PBC)
Beyond the preview
Go deeper on NCT02142127.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT02142127.